ArticleAIDS (London, England)2025
Antiretroviral-specific associations between bone hormonal changes and treatment induced weight gain.
Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Geriatric syndromes in women living with HIV.Current opinion in HIV and AIDS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundWeight gain is common in treatment naïve people with HIV (PWH) initiating antiretroviral therapy (ART). The mechanisms driving this weight gain are unclear. The current study tested the hypothesis that bone-derived hormones are associated with weight gain with ART initiation and that the associations are antiretroviral (ARV) specific.
methodsPlasma samples were obtained from the Advancing Clinical Therapeutics Globally (ACTG) study A5260s, in which treatment naïve PWH were initiated on tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) plus either atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or raltegravir (RAL). Plasma levels of bone-derived hormones, undercarboxylated osteocalcin (ucOCN), lipocalin-2 (NGAL), and sclerostin and body weight were measured at baseline and 48-weeks after ART initiation. The associations between change in bone-derived hormones and weight with ART initiation were assessed using linear regression models adjusted for age, sex, race, baseline viral load, and CD4 + cell count change.
resultsIncreases in ucOCN and decreases in NGAL were associated with weight change in PWH initiating ART. Sclerostin was not associated with weight change. When assessed as a function of ART, both ucOCN and NGAL were associated with weight for participants initiating RAL-based ART, but not ATV/r or DRV/r. After adjustment, the association between ucOCN and weight was no longer significant, while the association with NGAL remained statistically significant in RAL recipients.
conclusionsThis study suggests links between bone-derived hormones and ART induced weight gain in PWH and demonstrates that this relationship is influenced by specific antiretrovirals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.